CITATION REPORT List of articles citing

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiothe

DOI: 10.1016/0167-8140(92)90242-m Radiotherapy and Oncology, 1992, 25, 231-41.

Source: https://exaly.com/paper-pdf/23166167/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
602	Radiotherapeutic management in carcinoma of the uterine cervix: current status. 1993 , 3, 337-348		7
601	Extremity rhabdomyosarcoma: biological principles, staging, and treatment. 1993 , 9, 510-9		13
600	Alternating and concurrent chemotherapy and radiotherapy for unresectable head and neck carcinoma. 1993 , 1, 111-116		
599	Treatment-induced accelerated human tumor growth. 1993 , 3, 135-143		48
598	Dose intensification in curative head and neck cancer radiotherapylinear quadratic analysis and preliminary assessment of clinical results. 1993 , 27, 363-9		26
597	Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study. 1993 , 33, 203-9		10
596	Head and neck cancer. 1993 , 328, 1783; author reply 1784		10
595	Feasibility of curative radiotherapy with a concomitant boost technique in 33 patients with non-small cell lung cancer (NSCLC). <i>Radiotherapy and Oncology</i> , 1993 , 28, 247-51	5.3	25
594	The programme of quality assurance of the EORTC radiotherapy group. A historical overview. <i>Radiotherapy and Oncology</i> , 1993 , 29, 81-4	5.3	41
593	Beneficial liaisons: radiobiology meets cellular and molecular biology. <i>Radiotherapy and Oncology</i> , 1993 , 28, 1-15	5.3	30
592	Is hyperfractionation really better?. Radiotherapy and Oncology, 1993, 29, 354-5	5.3	1
591	High dose hyperfractionated radiotherapy for adults with glioblastomas. 1993 , 18, 99-105		2
590	Quantitative clinical radiobiology. 1993 , 32, 259-75		48
589	Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. 1994 , 33, 397-402		46
588	Proliferation equivalent of 'accelerated repopulation' in mouse oral mucosa. 1994 , 66, 157-67		91
587	Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. 1994 , 30, 1043-50		54
586	Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer. 1994 , 29, 45-	55	26

585	Idealized versus realized overall treatment times. 1994 , 29, 209-11; discussion 216	13
584	Early reactions as dose-limiting factors in radiotherapy. 1994 , 4, 55-67	25
583	Radiobiological considerations in the design of clinical trials. <i>Radiotherapy and Oncology</i> , 1994 , 32, 1-11 $_{5.3}$	93
582	Repopulation in mouse oral mucosa: treatment splits. <i>Radiotherapy and Oncology</i> , 1994 , 33, 139-47 5-3	18
581	The effect of very low radiation doses on the human bladder carcinoma cell line RT112. Radiotherapy and Oncology, 1994 , 32, 63-72 5-3	42
580	Patterns of fractionation for palliation of bone metastases. 1995 , 39, 31-5	23
579	Screening for cancer, 1995: An update. 1995 , 6, 551-557	14
578	Progress in radiotherapy. 1995 , 34, 1023-9	3
577	A 100-year Nordic perspective on the dose-time problem in radiobiology. 1995 , 34, 1031-40	5
576	Altered fractionation and extended-field irradiation of carcinoma of the cervix. 1995 , 76, 2152-8	5
575	Definitive radiotherapy for T1 and T2 squamous cell carcinoma of the tonsil. 1995 , 17, 334-8	16
574	A phase II trial evaluating selective use of altered radiation dose and fractionation in patients with unresectable rhabdomyosarcoma. 1995 , 31, 799-805	10
573	Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09. 1995 , 32, 589-97	49
572	Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. 1995 , 32, 577-88	59
571	Base-of-tongue carcinoma: treatment results using concomitant boost radiotherapy. 1995 , 33, 289-96	65
57°	Heterogeneity in the fractionation sensitivities of human tumor cell lines: studies in a three-dimensional model system. 1995 , 32, 395-408	17
569	Very accelerated radiation therapy: preliminary results in locally unresectable head and neck carcinomas. 1995 , 32, 747-52	29
568	The costs of hyperfractionation: an economic analysis incorporating consideration of waiting time for treatment. 1995 , 7, 162-7	5

567	Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules. 1995 , 31, 493-502	47
566	Early tolerance of different organs to fast fractionation in clinical practice. 1995 , 32, 1451-4	2
565	Interstitial brachytherapy in velo-tonsillar tumors: the ultimate boost. 1995 , 31, 1021-2; discussion 1023	3
564	Split-course accelerated therapy in head and neck cancer: an analysis of toxicity. 1995 , 32, 763-8	24
563	Hyperfractionated radiation in children with rhabdomyosarcomaresults of an Intergroup Rhabdomyosarcoma Pilot Study. 1995 , 32, 903-11	51
562	Split hyperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: a preliminary report. 1995 , 33, 675-82	11
561	Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. 1995 , 33, 549-62	12 0
560	Recent advances in radiation oncology. 1995 , 332, 371-9	103
559	A phase I/II study on hyperfractionated chemoradiation using chemotherapy as part of each fraction of treatment in locally far advanced head and neck cancer. 1995 , 31B, 401-2	5
558	The impact of lymph node metastases on the results of treatment by primary radiotherapy and secondary surgery in oropharyngeal cancer. 1995 , 34, 965-8	4
557	Effect of changing weekly dose on accelerated repopulation during fractionated irradiation of mouse tongue mucosa. 1995 , 67, 577-85	15
556	Effects of stimulated repopulation on oral mucositis during conventional radiotherapy. Radiotherapy and Oncology, 1995 , 37, 100-7 5-3	39
555	Curiethfapie des carcinomes pidermodes de l'oropharynx. 1995 , 82, 191-198	2
554	Hyperfractionation in the reirradiation of head and neck cancers. Result of a pilot study. <i>Radiotherapy and Oncology</i> , 1995 , 36, 203-10	45
553	Does the interval between fractions matter in the range of 4-8 h in radiotherapy? A study of acute and late human skin reactions. <i>Radiotherapy and Oncology</i> , 1995 , 34, 171-8	22
552	Radiothfapie hyperfractionne et acclfe dans les cancers de la tee et du cou: reultats des essais de l'EORTC et impact sur la pratique clinique. 1996 , 83, 314-320	11
551	Enhanced acute toxicity in oropharynx carcinoma treated with radiotherapy and concomitant cisplatin, 5-fluorouracil and mitomycin C. 1996 , 32A, 1707-11	4
550	Advances in cellular and molecular radiation oncology. 1996 , 2, 3-13	3

549 [Recent progress in radiotherapy]. **1996**, 17, 761-8

548	No age limit for radical radiotherapy in head and neck tumours. 1996 , 32A, 2075-81	122
547	Radiobiological basis, incidence and kinetics of acute mucosal reaction after different fractionation schemes. 1996 , 1, 67-71	2
546	Chapter 10: Future Developments in Radiotherapy. 1996 , 35, 75-83	1
545	Head and neck cancer. 1996 , 35 Suppl 7, 22-45	4
544	Chemotherapy of squamous cell carcinoma of head and neck: the future is now. 1996 , 7, 15-29	61
543	Early tumour response and treatment toxicity after hyperfractionated radiotherapy in nasopharyngeal carcinoma. 1996 , 69, 241-8	24
542	Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer. 1996 , 111, 123-31; discussion 131-3	44
541	Molecular biology of the cell cycle: Potential for therapeutic applications in radiation oncology. 1996 , 6, 284-294	19
540	Ionizing radiation and the cell cycle: A review. 1996 , 4, 147-158	1
539	Early squamous cell carcinoma of the hypopharynx: outcomes of treatment with radiation alone to the primary disease. 1996 , 18, 317-22	47
538	Local hyperthermia of N2/N3 cervical lymph node metastases: correlationof technical/thermal parameters and response. 1996 , 34, 635-46	50
537	One century of radiotherapy in France 1896-1996. 1996 , 35, 227-42	7
536	Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee. 1996 , 73, 1455-62	139
535	Accelerated radiation therapy for locally advanced squamous cell carcinomas of the oral cavity and oropharynx selected according to tumor cell kineticsa phase II multicenter study. 1996 , 36, 1137-45	21
534	Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer. 1996 , 35, 425-38	34
533	Alternative fractionation schemes is the "gap" the way ?. 1996 , 35, 629-30	
532	Review article: effects of radiation on the cell proliferation kinetics of epithelial tissuestherapeutic implications. 1996 , 69, 795-803	20

531	Combined concomitant boost radiotherapy and chemotherapy in stage III-IV head and neck carcinomas: a comparison of toxicity and treatment results with those observed after radiotherapy alone. 1997 , 8, 681-4		12
530	Fractionation in radiotherapy: a view from the clinic. 1997 , 70 Spec No, S17-24		1
529	Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy. <i>Radiotherapy and Oncology</i> , 1997 , 42, 155-61	5.3	117
528	Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. <i>Radiotherapy and Oncology</i> , 1997 , 44, 111-21	5.3	395
527	Hyperfractionation: where do we stand?. Radiotherapy and Oncology, 1997, 43, 1-21	5.3	50
526	A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer. <i>Radiotherapy and Oncology</i> , 1997 , 43, 39-46	5.3	131
525	Is acute mucositis a dose limiting factor in altered fractionated radiotherapy?. 1997 , 2, 65-69		
524	Messages from completed randomized trials in head and neck cancer. 1997 , 23, 469-76		9
523	Acute and consequential mucosal radiation reactions in patients with head and neck cancer treated by continuous accelerated irradiation (CAIR). 1997 , 2, 11-20		
522	[Late effects of ionizing radiations on head and neck region tissues]. 1997 , 1, 692-705		1
521	[Hyperfractionated reirradiation after salvage surgery in cervico-facial carcinoma. Result of a pilot study in 14 patients]. 1997 , 1, 68-73		7
520	[Effect radiotherapy on postoperative staging and residual tumor cell density in rectal cancers]. 1997 , 1, 240-8		O
519	Nonstandard Fractionation Schedules in Radiation Therapy of Head and Neck Cancer: A Review. 1997 , 83, 633-642		2
518	The Role of Chemotherapy in the Curative Treatment of Head and Neck Cancer. 1997 , 6, 749-768		14
517	Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. 1997 , 37, 259-67		106
516	Concomitant infusion cisplatin and hyperfractionated radiotherapy for locally advanced nasopharyngeal and paranasal sinus tumors. 1997 , 39, 823-9		29
515	Clinical science and patient care: lessons from cooperative randomized clinical trials. 1997 , 39, 273-4		1
514	[A phase-I/II study on the local hyperthermia of cervical N2/N3 lymph node metastases]. 1997 , 173, 219	9-29	2

513	Fractionation experiments in head and neck cancer: the lessons so far. 1997 , 9, 302-7	1
512	Late rectal sequelae following definitive radiation therapy for carcinoma of the uterine cervix: a dosimetric analysis. 1997 , 37, 351-8	86
511	Preoperative radiotherapy (RT) for rectal cancer: predictive factors of tumor downstaging and residual tumor cell density (RTCD): prognostic implications. 1997 , 37, 619-27	172
510	Complications following definitive irradiation for cancers of the oral cavity and the oropharynx (in a series of 1134 patients). 1997 , 37, 577-85	51
509	External beam radiation therapy for squamous cell carcinoma of the soft palate. 1997 , 38, 507-11	2
508	Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. 1997 , 37, 1005-10	87
507	Long-term regional control after radiation therapy and neck dissection for base of tongue carcinoma. 1997 , 38, 995-1000	48
506	Concomitant boost radiotherapy for squamous carcinoma of the tonsillar fossa. 1997 , 39, 127-35	35
505	Applying radiobiological principles to combined modality treatment of head and neck cancerthe time factor. 1997 , 39, 831-6	98
504	Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. 1997 , 5, 235-45	32
503	Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma. 1997 , 79, 1401-1408	21
502	Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/-granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma. 1997 , 80, 266-76	32
501	A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck. 1998 , 16, 161-9	16
500	A prospective quality of life study of patients with laryngeal carcinoma by tumor stage and different radiation therapy schedules. 1998 , 108, 747-59	76
499	Scoring oral mucositis. 1998 , 34, 63-71	92
498	Altered fractionation trials in head and neck cancer. 1998 , 8, 230-6	69
497	Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. 1998 , 8, 237-46	45
496	Toxicity antagonists in head and neck cancer. 1998 , 8, 282-91	11

495	Hyperfractionated radiotherapy and simultaneous cisplatin for stage-III and -IV carcinomas of the head and neck. Long-term results including functional outcome. 1998 , 174, 397-402	25
494	Induction chemotherapy followed by simultaneous hyperfractionated radiochemotherapy in advanced head and neck cancer. A pilot study. 1998 , 174, 457-61	4
493	Head and neck cancer: surgery or radiotherapy?. 1998 , 10, 139-40	3
492	Altered radiotherapy fractionation: an opportunity not to be missed. 1998 , 10, 150-4	3
491	Correspondence. 1998 , 40, 257	1
490	Correspondence. 1998 , 40, 257-259	2
489	Granulocyte macrophage-colony-stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy. 1998 , 41, 747-54	38
488	Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. 1998 , 42, 79-85	250
487	Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study. 1998 , 42, 237-45	22
486	Carcinoma of the tonsillar fossa: prognostic factors and long-term therapy outcome. 1998 , 42, 1077-84	63
485	[Chemoradiotherapy of carcinomas of the upper aerodigestive tract]. 1998, 2, 679-88	7
484	A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer. 1998 , 20, 37-46	4
483	A PHASE I/II TRIAL OF TRANSURETHRAL SURGERY COMBINED WITH CONCURRENT CISPLATIN, 5-FLUOROURACIL AND TWICE DAILY RADIATION FOLLOWED BY SELECTIVE BLADDER PRESERVATION IN OPERABLE PATIENTS WITH MUSCLE INVADING BLADDER CANCER. 1998, 160, 1673-167	65 7
482	Current Scientific Issues Related to Clinical Radiation Oncology. 1998 , 150, 125	6
481	Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. Radiotherapy and Oncology, 1998 , 46, 127-30 5-3	34
480	Hyperfractionation: where do we stand?. <i>Radiotherapy and Oncology</i> , 1998 , 46, 131-3 5.3	5
479	New insights into factors influencing the clinically relevant oxygen enhancement ratio. Radiotherapy and Oncology, 1998 , 46, 269-77 5-3	49
478	Tumor response, mucosal reactions and late effects after conventional and hyperfractionated radiotherapy and Oncology, 1998 , 47, 137-43	26

477	Correspondence. Radiotherapy and Oncology, 1998 , 47, 104-107	5.3	
476	Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. <i>Radiotherapy and Oncology</i> , 1998 , 47, 175-83	5.3	78
475	Improving dose homogeneity in routine head and neck radiotherapy with custom 3-D compensation. <i>Radiotherapy and Oncology</i> , 1998 , 49, 67-71	5.3	15
474	Concomitant boost radiotherapy in oropharynx carcinomas. 1998 , 37, 687-91		1
473	Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. 1998 , 338, 1798-804		942
472	Altered fractionation in radiation therapy for squamous-cell carcinoma of the head and neck. 1998 , 16, 594-603		23
471	Where there's smoke, is there fire?. 1998 , 14, 589-91		5
47°	Randomized Trials on Altered Fractionation in Head and Neck Cancer Radiotherapy with Conventional Fractionation as Control Arm: Another Lap to Go. 1998 , 84, 160-166		1
469	Altered Fractionation in Radiotherapy. 1998 , 84, 155-159		2
468	Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses. 1999 , 17, 2390-5		47
467	Standard effective doses for proliferative tumours. 1999 , 44, 2127-42		1
466	Local-regional control by conventional radiotherapy according to tumor volume in patients with squamous cell carcinoma of the pharyngolarynx. 1999 , 29, 467-73		5
465	Benefits of accelerated hyperfractionation for head and neck cancer. 1999 , 38, 131-6		8
464	Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide. 1999 , 38, 875-82		27
463	Hyper-fractionated radiotherapy for soft tissue sarcoma: results of the second study of hyper-fractionated radiotherapy. 1999 , 3, 157-65		6
462	Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. 1999 , 91, 2081-6		887
461	Superfractionation as a potential hypoxic cell radiosensitizer: prediction of an optimum dose per fraction. 1999 , 43, 1083-94		23
460	Local-regional control of recurrent breast carcinoma after mastectomy: does hyperfractionated accelerated radiotherapy improve local control?. 1999 , 44, 105-12		31

459	Chemotherapy alternated with radiotherapy in the treatment of advanced head and neck carcinoma: predictive factors of outcome. 1999 , 44, 139-47	7
458	Accelerated hyperfractionated radiotherapy for locally advanced cervix cancer. 1999 , 44, 519-24	18
457	Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. 1999 , 45, 21-32	250
456	Avoidance of treatment interruption: an unrecognized benefit of accelerated radiotherapy in oropharyngeal carcinomas?. 1999 , 45, 41-5	21
455	Accelerated radiotherapy with delayed concomitant boost in locally advanced squamous cell carcinoma of the head and neck. 1999 , 45, 589-95	14
454	Prognostic impact of complete remission after preoperative irradiation of tonsillar carcinoma: a retrospective analysis of the radiumhemmet data, 1980-1995. 1999 , 45, 1259-66	10
453	The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. 1999 , 45, 857-65	183
452	Syndecan-1 expression has prognostic significance in head and neck carcinoma. 1999 , 79, 558-64	107
451	High-dose-rate brachytherapy for primary carcinomas of the oral cavity and oropharynx. 1999 , 109, 1967-73	34
450	Low-energy He/Ne laser in the prevention of radiation-induced mucositis. A multicenter phase III randomized study in patients with head and neck cancer. 1999 , 7, 244-52	171
449	Altered fractionation in the treatment of head and neck cancer. 1999 , 1, 110-23	7
448	The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. 1999 , 35, 203-8	26
447	Preoperative concurrent chemoradiotherapy plus radical surgery for advanced squamous cell carcinoma of the oral cavity: an analysis of long-term results. 1999 , 35, 597-606	38
446	Cancer of the base of the tongue: Past and future. 1999 , 21, 751-759	10
445	Hyperfractionated radiotherapy: tops or flops?. 1999 , 33, 399-402	5
444	Radiotherapy: the last 25 years. 1999 , 25, 365-76	21
443	Towards prediction and modulation of treatment response. <i>Radiotherapy and Oncology</i> , 1999 , 50, 1-11 5.3	25
442	Altered fractionation: limited by mucosal reactions?. <i>Radiotherapy and Oncology</i> , 1999 , 50, 247-60 5.3	54

(2000-1999)

441	Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomized hyperfractionation trials. <i>Radiotherapy and Oncology</i> , 1999 , 51, 113-21	5.3	43
440	Cancer of the tonsil: the results of ipsilateral radiation treatment. <i>Radiotherapy and Oncology</i> , 1999 , 51, 123-8	5-3	76
439	Caution on the use of altered fractionation for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 1999 , 52, 207-11	5.3	22
438	Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. <i>Radiotherapy and Oncology</i> , 1999 , 53, 219-26	5.3	101
437	Differential effects of the insulin-like growth factor I receptor on radiosensitivity and spontaneous necrosis formation of human glioblastoma cells grown in multicellular spheroids. 1999 , 250, 99-111		9
436	Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. 2000 , 18, 3339-45		668
435	Altered fractionation in definitive irradiation of squamous cell carcinoma of the head and neck. 2000 , 12, 207-14		25
434	Improved results with accelerated hyperfractionated radiotherapy of advanced head and neck cancer. 2000 , 90, 80-91		9
433	High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy in patients with locally advanced primary squamous cell carcinoma of the head and neck: report of a phase II study. 2000 , 22, 543-9		16
432	Confirmation of improved local-regional control with altered fractionation in head and neck cancer. 2000 , 48, 3-6		30
431	A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. 2000 , 48, 7-16		1075
430	Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications. 2000 , 48, 1311-22		103
429	Granulocyte macrophage-colony stimulating factor (GM-CSF) and sucralfate in prevention of radiation-induced mucositis: a prospective randomized study. 2000 , 46, 525-34		74
428	Toxicity in head and neck cancer: a review of trends and issues. 2000 , 47, 1-12		250
427	An original accelerated radiotherapy schedule in stage III to IV head and neck cancers. Results in a multicenter setting. 2000 , 176, 28-31		3
426	Treatment of Cancer of the Base of the Tongue and Glosso-Epiglottic Region: A Multicenter Italian Survey. 2000 , 86, 215-223		2
425	Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. 2000 , 18, 1458-	64	387
424	Advances in Radiotherapy for Carcinoma of the Head and Neck. 2000 , 9, 563-575		7

423	Simultaneous radiochemotherapy versus concomitant boost radiation for advanced inoperable head and neck cancer. 2000 , 39, 523-8		3
422	Squamous cell carcinoma of the oropharynxan analysis of treatment results in 289 consecutive patients. 2000 , 39, 985-94		39
421	Hypopharyngeal squamous cell carcinomatreatment results in 138 consecutively admitted patients. 2000 , 39, 529-36		70
420	Comments on 'Standard effective doses for proliferative tumours'. 2000 , 45, L45-50		2
419	THE CURRENT STATUS OF BLADDER PRESERVATION IN THE TREATMENT OF MUSCLE INVASIVE BLADDER CANCER. 2000 , 164, 627-632		42
418	Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity. <i>Radiotherapy and Oncology</i> , 2000 , 55, 101-10	5.3	125
417	Ipsilateral irradiation for carcinomas of tonsillar region and soft palate based on computed tomographic simulation. <i>Radiotherapy and Oncology</i> , 2000 , 54, 117-21	5.3	36
416	Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2000 , 54, 123-7	5.3	50
415	Hyperfractionated or accelerated radiotherapy for head and neck cancer. 2010 , CD002026		25
414	Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): report on 3-year tumor control and normal tissue toxicity. <i>Radiotherapy and Oncology</i> , 2001 , 58, 121-30	5.3	50
413	Quantification of late complications after radiation therapy. Radiotherapy and Oncology, 2001, 61, 233-	46 .3	95
412	Biological factors influencing optimum fractionation in radiation therapy. 2001 , 40, 712-7		102
411	Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer. 2001 , 33 Suppl 1, S35-45		22
410	Head and neck cancer. 2001 , 345, 1890-900		1045
409	Programming of radiotherapy in the treatment of non-small-cell lung cancera way to advance care. 2001 , 2, 401-8		5
408	Advanced oropharyngeal carcinoma treated with surgery and radiotherapy: oncologic outcome and functional assessment. 2001 , 22, 329-35		45
407	A Radiation Therapy Oncology Group (RTOG) phase III randomised study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas; first report of RTOG 9003. 2001 , 5, 95-96		1
406	[Comments on five clinical trials concerning radiotherapy-induced mucositis in patients with head and neck neoplasms]. 2001 , 5, 202-4		

(2001-2001)

405	[Randomized clinical trial on 7-day continuous accelerated irradiation (CAIR) of head and neck cancer. Report on 3-year tumour control and normal tissue toxicity]. 2001 , 5, 207-8	1
404	[Concomitant bifractionated radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in locally progressive, non-resectable epidermoid carcinomas of the pharynx: ten years experience at the Antoine Lacassagne center]. 2001 , 5, 413-24	O
403	Organ preservation for carcinoma of the larynx and hypopharynx. 2001 , 15, 243-60, v	11
402	How the game is playedchallenge between therapeutic benefit and acute toxicity in fractionated radiotherapy. 2002 , 37, 174-84	
401	Recent Advances in Radiotherapy for Head and Neck Cancers. 2001, 80, 704-719	3
400	High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. 2001 , 19, 3333-9	27
399	Does histologic grade have a role in the management of head and neck cancers?. 2001 , 19, 4107-16	55
398	Concurrent chemoradiotherapy for oropharyngeal carcinoma. 2001 , 24, 71-6	6
397	Konventionell und unkonventionell fraktionierte alleinige Strahlentherapie bei Plattenepithelkarzinomen des Pharynx und Larynx. 2001 , 7, 550-556	1
396	Chemotherapy- and radiotherapy-induced mucositis in head and neck cancer patients: new trends in pathophysiology, prevention and treatment. 2001 , 258, 481-7	42
395	Relationship between tumor radioresistance and cell kinetics in fractionated radiotherapy. 2001 , 17, 38-42	
394	The use of the linear quadratic model in radiotherapy: a review. 2001 , 24, 132-46	42
393	Prophylaxis of oral mucositis in irradiated head-and-neck cancer patients: a proposed classification scheme of interventions and meta-analysis of randomized controlled trials. 2001 , 49, 917-30	76
392	The translational research chain: is it delivering the goods?. 2001 , 49, 345-51	26
391	Normal tissue radiobiology: from the laboratory to the clinic. 2001 , 49, 353-65	71
390	Hyperfractionated chemoradiation with carbogen breathing, with or without erythropoietin: a stepwise developed treatment schedule for advanced head-and-neck cancer. 2001 , 50, 47-53	12
389	Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage III non-small-cell lung cancer. 2001 , 50, 295-300	7
388	Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. 2001 , 50, 343-52	62

387	Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapyresults of a multicentric randomized German trial in advanced head-and-neck cancer. 2001 , 50, 1161-71		304
386	Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better?. 2001 , 51, 1200-8		41
385	A comparison of surgery and radiotherapy in the management of advanced pyriform fossa carcinoma. 2001 , 26, 59-61		8
384	Potential molecular prognostic markers in head and neck squamous cell carcinomas. 2001 , 23, 147-59		119
383	Surgical treatment of squamous cell carcinoma of the base of tongue. 2001 , 23, 653-60		55
382	Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcomaa report from the IRSG. 2001 , 51, 718-28		171
381	Head and Neck Cancer Committee. 2001 , 51, 39-43		
380	Long-term outcome of 56 dogs with nasal tumours treated with four doses of radiation at intervals of seven days. 2002 , 151, 253-7		39
379	Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III, randomized, controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. 2002 , 20, 3956-63		57
378	Concomitant chemoradiotherapy in pyriform sinus carcinoma. 2002 , 128, 384-8		30
377	A phase II study of concomitant hyperfractionated radiation therapy and double dose intra-arterial cisplatin for squamous cell carcinoma of the head and neck. 2002 , 1, 133-40		3
376	Prognostic factors in squamous cell carcinoma of the head and neck. 2002 , 25, 208-12		11
375	A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2002 , 63, 187-93	5.3	18
374	Twice-a-day radiotherapy for head and neck cancer: the Catalan Institute of Oncology experience. <i>Radiotherapy and Oncology</i> , 2002 , 64, 19-27	5.3	3
373	Intensity modulated radiotherapy (IMRT) decreases treatment-related morbidity and potentially enhances tumor control. 2002 , 20, 437-51		50
372	Radiotherapy for cancer of the head and neck: altered fractionation regimens. 2002 , 3, 693-701		81
371	Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. 2002 , 6, 325-326		
370	Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial. 2002 , 6, 326-32	28	

(2003-2002)

369	Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial. 2002 , 38, 667-73	26
368	From chemoprevention and organ preservation programmes to postoperative management: major achievements and strategies of the EORTC Head and Neck Cancer Group. 2002 , 38 Suppl 4, S75-81	53
367	Organ preservation trials for laryngeal cancer. 2002 , 35, 1035-54, vi	6
366	The Role of Brachytherapy in the Management of Oropharyngeal Carcinomas: The Trento Experience. 2002 , 88, 137-141	5
365	Perspektiven und Entwicklungen in der Radioonkologie der letzten 25 Jahre. 2002 , 25, 15-20	
364	Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer. 2002 , 63, 115-23	5
363	Comparison of Radiation-Induced Oral Mucositis Scoring Systems. 2002 , 88, 379-384	9
362	A pilot study evaluating the safety and microbiologic efficacy of an economically viable antimicrobial lozenge in patients with head and neck cancer receiving radiation therapy. 2002 , 24, 6-15	16
361	Pilot trial of concomitant chemotherapy with paclitaxel and split-course radiotherapy for very advanced squamous cell carcinoma of head and neck. 2002 , 24, 228-35	8
360	Changes in presentation and survival of head and neck carcinomas in Northeastern Italy, 1975-1998. 2002 , 95, 540-52	10
359	Cancer of the oropharynx. 2002 , 41, 107-22	48
358	Parotid lymph-node metastases from cutaneous squamous-cell carcinomas: treatment outcome and prognostic factors following surgery and adjuvant radiotherapy. 2002 , 46, 174-9	24
357	Hyperfractionated-accelerated or conventionally fractionated radiotherapy for early glottic cancer. 2002 , 52, 109-19	20
356	Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. 2002 , 52, 739-47	178
355	Dose escalation using twice-daily radiotherapy for nasopharyngeal carcinoma: does heavier dosing result in a happier ending?. 2002 , 54, 14-22	27
354	Preoperative hyperfractionated radiotherapy for locally advanced rectal cancers: a phase I-II trial. 2002 , 54, 1076-81	21
353	Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. 2002 , 53, 344-52	34
352	Topical application of honey in the management of radiation mucositis: a preliminary study. 2003 , 11, 242-8	133

351	Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS). 2003 , 179, 832-9	32
350	Current management of tonsillar cancer. 2003 , 39, 337-42	19
349	Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer?. 2003 , 44, 57-64	36
348	Distant metastases after definitive radiotherapy for squamous cell carcinoma of the head and neck. 2003 , 25, 629-33	35
347	Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapya multicenter randomized trial. 2003 , 55, 78-92	96
346	Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment?. 2003 , 55, 322-8	115
345	Swallowing dysfunctionpreventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review. 2003 , 57, 1219-30	171
344	Metastatic cutaneous squamous cell carcinoma to the parotid: the role of surgery and adjuvant radiotherapy to achieve best outcome. 2003 , 73, 692-6	48
343	Developments in radiotherapy and adjuvant chemotherapy for head and neck cancer. 2003, 28, 1-4	
342	Altered fractionation and/or adjuvant chemotherapy in definitive irradiation of squamous cell carcinoma of the head and neck. 2003 , 113, 546-51	51
341	Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas. 2003 , 55, 568-75	41
340	Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (SOD2) transgene. 2003 , 159, 361-70	91
339	Clinical promise tempered by reality in the delivery of combined chemoradiation for common solid tumors. 2003 , 13, 3-12	13
338	Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. 2003 , 362, 933-40	506
337	Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. 2003 , 39, 560-71	75
336	Childhood nasopharyngeal carcinoma: from biology to treatment. 2003 , 4, 13-21	133
335	Promising New Approaches in the Treatment of Advanced Head and Neck Cancer. 2003 , 2, 335-347	1
334	Hyperfractionated radiation therapy for hypopharyngeal carcinoma compared with conventional radiation therapy: local control, laryngeal preservation and overall survival. 2003 , 33, 450-5	8

333 Combination of Chemotherapy with Radiation for Head and Neck Cancer. **2003**, 445-460

332	Management of chemo- and radiotherapy induced oral mucositis with low-energy laser: initial results of A.C. Camargo Hospital. 2003 , 11, 337-41	25
331	Defining the tumour and target volumes for radiotherapy. 2004 , 4, 153-61	90
330	Chemoradiation in locally advanced head and neck cancer: new evidence, new challenges. 2004 , 4, 335-9	5
329	Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. 2004 , 22, 3540-8	65
328	Hyperfractionated radiation therapy for oropharyngeal carcinoma in a Japanese population. 2004 , 34, 312-5	1
327	Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: are we addressing burning subjects?. 2004 , 22, 4657-9	84
326	Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. 2004 , 22, 4665-73	205
325	Head and neck cancer. 2004 , 15 Suppl 4, iv267-73	7
324	Phase I study of hyperfractionated radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer. 2004 , 67, 215-21	6
323	A long-term follow-up study after split-course irradiation with concurrent chemotherapy (carboplatin) for locally advanced head and neck cancer and a review of the literature. 2004 , 66, 325-31	3
322	Radiation oncology: a century of achievements. 2004 , 4, 737-47	384
321	Concomitant radiochemotherapy or accelerated radiotherapy: analysis of two randomized trials of the French Head and Neck Cancer Group (GORTEC). 2004 , 31, 822-6	40
320	Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. 2004 , 9, 107-12	56
319	Hyperfractionated radiotherapy for head and neck cancer: general results of theCatalan Institute of Oncology (ICO). 2004 , 6, 424-434	
318	Hyperfractionated radiotherapy in locally advanced nasopharyngeal cancer. An analysis of 43 consecutive patients. 2004 , 180, 425-33	12
317	Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for Stage III and IVA head-and-neck cancer in the community. 2004 , 58, 698-704	33
316	Concomitant radiochemotherapy in primary inoperable advanced head and neck cancer with 5-fluorouracil and mitomycin-C. 2004 , 26, 845-53	12

315	Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. 2004 , 59, 28-42		267
314	Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. 2004 , 60, 1405-9		29
313	Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations. 2004 , 28, 7-40		15
312	Radiobiological rationale and patient selection for high-LET radiation in cancer therapy. <i>Radiotherapy and Oncology</i> , 2004 , 73 Suppl 2, S1-14	5.3	18
311	Oral complications of radiotherapy in head and neck cancer. 2004 , 3, 291-298		О
310	Altered fractionated radiotherapy in the management of head and neck carcinomas: advantages and limitations. 2004 , 16, 215-9		31
309	Prevention and treatment of oropharyngeal mucositis following cancer therapy: are there new approaches?. 2004 , 27, 183-205		31
308	Modified fractionated radiotherapy in head and neck squamous cell carcinoma (HNSCC) & re-irradiation in recurrent head and neck carcinomas. 2003 , 114, 199-212		4
307	The use of intensity-modulated radiation therapy in the treatment of oropharyngeal carcinoma. 2005 , 13, 226-32		4
306	Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. 2005 , 61, 762-71		64
305	Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants. 2005, 62, 665-71		40
304	Treatment of recurrent head and neck cancer: re-irradiation or chemotherapy?. 2005 , 17, 138-47		24
303	Diffusion tensor imaging: possible implications for radiotherapy treatment planning of patients with high-grade glioma. 2005 , 17, 581-90		60
302	Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. 2005 , 27, 36-43		63
301	Evolving treatment strategies for parameningeal rhabdomyosarcoma: the experience of the Istituto Nazionale Tumori of Milan. 2005 , 27, 49-57		16
300	Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. 2005 , 104, 1418-27		10
299	Combined modality treatment with full-dose chemotherapy and concomitant boost radiotherapy for advanced head and neck carcinoma. 2005 , 262, 1-7		8
298	Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas. Preliminary results of a phase II, single-institutional trial. 2005 , 7, 60-5		4

(2006-2005)

297	Altered Fractionation Radiotherapy in Head and Neck Cancer: Clinical Issues and Pitfalls of Evidence-Based Medicine (2005, 91, 30-39)	2
296	Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology?. 2005 , 2, 305-14	29
295	Head and neck squamous cell carcinoma: optimizing the therapeutic index. 2005 , 5, 501-14	14
294	Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2005 , 77, 32-8	29
293	Proton therapy of cancer: potential clinical advantages and cost-effectiveness. 2005, 44, 850-61	112
292	Head and neck oncology: what the past decade has taught us. 2006 , 6, 1133-6	6
291	Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. 2006, 368, 843-54	822
2 90	Altered fractionation: a fractional benefit?. 2006 , 368, 819-21	
289	Selected topics in head and neck cancer. 2006 , 3, 644-650	2
288	Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: a prospective phase II study. <i>Radiotherapy and Oncology</i> , 2006 , 78, 146-51	10
287	Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. <i>Radiotherapy and Oncology</i> , 2006 , 78, 236-44	134
286	A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. <i>Radiotherapy and Oncology</i> , 2006 , 79, 34-8	46
285	Introduction to clinical radiation biology. 2006 , 20, 1-24	45
284	Long-Term Results of Conventional Radiotherapy versus Accelerated Hyperfractionated Radiotherapy versus Concomitant Radiotherapy and Chemotherapy in Locoregionally Advanced Carcinoma of the Oropharynx. 2006 , 92, 41-54	27
283	Radiotherapy for head and neck cancer: latest developments and future perspectives. 2006 , 18, 240-6	15
282	A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancer. 2006 , 29, 423-30	32
281	Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer. 2006 , 12, 63-8	10
280	Changing failure patterns in oropharyngeal squamous cell carcinoma treated with intensity modulated radiotherapy and implications for future research. 2006 , 29, 606-12	41

279	Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma. 2006 , 116, 1651-6	22
278	Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment. 2006 , 18, 93-103	51
277	National survey of radiotherapy fractionation practice in 2003. 2006 , 18, 3-14	52
276	French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). 2006 , 64, 983-94	108
275	Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. 2006 , 64, 1308-16	71
274	Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. 2006 , 66, 706-13	53
273	Is there a "mucosa-sparing" benefit of IMRT for head-and-neck cancer?. 2006 , 66, 931-8	53
272	Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region. 2006 , 23, 1-15	13
271	Hyperfractionated-accelerated radiotherapy followed by radical surgery in locally advanced tumors of the oral cavity. 2006 , 182, 157-63	13
270	The impact on oncology of the interaction of radiation therapy and radiobiology. 2006 , 8, 83-93	4
269	A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. 2006 , 6, 28	201
268	Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. 2006 , 106, 329-36	248
267	Cetuximab plus radiotherapy for head and neck cancer. 2006 , 354, 2187; author reply 2187	4
266	Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. 2006 , 24, 2873-8	112
265	Practical Time-Dose Evaluations, or How to Stop Worrying and Learn to Love Linear Quadratics. 2006 , 3-31	8
264	Chemo-radiotherapy in head and neck cancer. 2006 , 17 Suppl 10, x39-41	15
263	Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. 2006 , 24, 2612-7	78
262	IMRT for Carcinomas of the Oropharynx and Oral Cavity. 2006 , 301-317	

261	Accelerated radiotherapy and larynx preservation in favorable-risk patients with T2 or worse hypopharyngeal cancer. 2007 , 37, 345-52	9
260	Combined modality treatment of laryngeal squamous cell carcinoma. 2007 , 7, 331-50	13
259	Commentary: IMRT for head and neck cancer: many chapters left to write. 2007 , 12, 565-8	4
258	[Concurrent chemoradiotherapy for squamous cell carcinoma of the oropharynx]. 2007, 110, 635-42	5
257	Individual patients' data meta-analyses in head and neck cancer. 2007 , 19, 188-94	88
256	Recent advances in combined modality therapy for locally advanced head and neck cancer. 2007 , 7, 674-80	8
255	Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?. 2007 , 43, 35-45	50
254	Results of a prospective randomised trial comparing conventional radiotherapy to split course bifractionated radiation therapy in patients with nasopharyngeal carcinoma. <i>Radiotherapy and 5.3 Oncology</i> , 2007 , 85, 17-23	21
253	Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2007 , 85, 7-16	54
252	Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer. 2007 , 14, 424-31	16
251	4 Radiotherapy fractionation. 2007 , 51-78	5
250	2 Review of essential and topical radiobiology. 2007 , 12-34	
249	Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. 2007 , 29, 211-20	71
248	Early experience with a hybrid accelerated radiotherapy schedule for locally advanced head and neck cancer. 2007 , 29, 720-30	13
247	Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling. 2007 , 19, 8-22	46
246	How much radiation is the chemotherapy worth in advanced head and neck cancer?. 2007 , 68, 1491-5	60
245	Locally advanced tonsillar squamous cell carcinoma: Treatment approach revisited. 2007, 117, 45-50	28
244	Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). 2007 , 60, 399-406	20

243	Radiochemotherapie als Behandlungsstandard fortgeschrittener Kopf-Hals-Karzinome. 2007, 13, 165-173	3
242	Favorable survival observed after carboplatin, paclitaxel, and concurrent accelerated hyperfractionated radiotherapy for treatment of locally advanced head and neck carcinoma. 2008 , 26, 473-81	8
241	Carcinomes des voies afodigestives supfieures: nouvelles approches en radiothfapie. 2008 , 10, 8-15	
240	Concurrent hyperfractionated radiotherapy and carboplatin with transoral debulking microsurgery for T2N0 glottic cancer. 2008 , 30, 1027-34	3
239	Palliative radiation therapy for head and neck cancer: toward an optimal fractionation scheme. 2008 , 30, 1586-91	47
238	CHART revisited: a conservative approach for advanced head and neck cancer. 2008 , 20, 127-33	6
237	Chemoradiation for advanced head and neck cancer: potential for improving results to match those of current treatment modalities for early-stage tumorslong-term results of hyperfractionated chemoradiation with carbogen breathing and anemia correction with erythropoietin. 2008 , 70, 1382-8	4
236	Clinical experience using hypofractionated radiation schedules in breast cancer. 2008 , 18, 257-64	59
235	Treatment of patients with unresectable squamous head and neck cancer with induction chemotherapy followed by hyperfractionated radiotherapy. 2008 , 12, 88-95	4
234	Comparison of cervical esophagus dose-volumes for three radiotherapy techniques for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2008 , 87, 274-80	6
234		16
	neck cancer. <i>Radiotherapy and Oncology</i> , 2008 , 87, 274-80	
233	neck cancer. <i>Radiotherapy and Oncology</i> , 2008 , 87, 274-80 Radiotherapeutic management of laryngeal carcinoma. 2008 , 41, 715-40, vi Radiotherapy treatment delays and their influence on tumour control achieved by various	16
233	neck cancer. <i>Radiotherapy and Oncology</i> , 2008 , 87, 274-80 Radiotherapeutic management of laryngeal carcinoma. 2008 , 41, 715-40, vi Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. 2008 , 81, 549-63	16 27
233 232 231	Radiotherapeutic management of laryngeal carcinoma. 2008, 41, 715-40, vi Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. 2008, 81, 549-63 Radiation treatment breaks and ulcerative mucositis in head and neck cancer. 2008, 13, 886-98	16 27 140
233 232 231 230	Radiotherapeutic management of laryngeal carcinoma. 2008, 41, 715-40, vi Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. 2008, 81, 549-63 Radiation treatment breaks and ulcerative mucositis in head and neck cancer. 2008, 13, 886-98 Options for combining altered fractionation with IMRT. 2008, 7, 457-61 Gap compensation during accelerated hypofractionated radiotherapy in head and neck cancer.	16 27 140
233 232 231 230 229	Radiotherapeutic management of laryngeal carcinoma. 2008, 41, 715-40, vi Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules. 2008, 81, 549-63 Radiation treatment breaks and ulcerative mucositis in head and neck cancer. 2008, 13, 886-98 Options for combining altered fractionation with IMRT. 2008, 7, 457-61 Gap compensation during accelerated hypofractionated radiotherapy in head and neck cancer. 2008, 7, 31-38	16 27 140 1

225	The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. 2008 , 19, 129-34	16
224	The Impact of Tumor Biology on Cancer Treatment and Multidisciplinary Strategies. 2009,	10
223	Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. 2009 ,	
222	Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series. 2009 , 76, 405-12	6
221	Current concepts of management in radiotherapy for head and neck squamous-cell cancer. 2009 , 45, 402-8	40
220	Induction chemotherapy: to use or not to use? That is the question. 2009 , 19, 11-6	16
219	Treatment of head and neck cancers: issues for clinical pharmacists. 2009 , 29, 578-92	18
218	Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma. 2009 , 31, 167-74	16
217	Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. 2009 , 266, 1845-55	61
216	[Radiotherapy, chemotherapy and target therapy for treatment of head and neck cancer: new developments]. 2009 , 57, 436-45	3
215	Linear quadratic and tumour control probability modelling in external beam radiotherapy. 2009 , 58, 799-817	62
215		
	Linear quadratic and tumour control probability modelling in external beam radiotherapy. 2009 , 58, 799-817	62
214	Linear quadratic and tumour control probability modelling in external beam radiotherapy. 2009 , 58, 799-817 Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. 2009 , 9, 134-42 Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and	62 450
214	Linear quadratic and tumour control probability modelling in external beam radiotherapy. 2009 , 58, 799-817 Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. 2009 , 9, 134-42 Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck. 2009 , 15, 121-32 Pattern analysis of acute mucosal reactions in patients with head and neck cancer treated with	62 45° 27
214	Linear quadratic and tumour control probability modelling in external beam radiotherapy. 2009, 58, 799-817 Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. 2009, 9, 134-42 Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck. 2009, 15, 121-32 Pattern analysis of acute mucosal reactions in patients with head and neck cancer treated with conventional and accelerated irradiation. 2009, 73, 384-90	62 450 27 28
214 213 212 211	Linear quadratic and tumour control probability modelling in external beam radiotherapy. 2009, 58, 799-817 Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. 2009, 9, 134-42 Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck. 2009, 15, 121-32 Pattern analysis of acute mucosal reactions in patients with head and neck cancer treated with conventional and accelerated irradiation. 2009, 73, 384-90 In Reply to Dr. Hartley. 2009, 75, 315 Modeling the contribution of synchronous chemotherapy to the rate of grade 3 and 4 mucositis in	62 450 27 28

207	Radiation therapy for head and neck cancers. 2009 , 25, 193-202	16
206	Advances in radiotherapy and implications for the next century: a historical perspective. 2009 , 69, 383-92	145
205	Incidence of isolated regional recurrence after definitive (chemo-) radiotherapy for head and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2009 , 93, 498-502	38
204	Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. 2009 , 10, 341-50	118
203	Multimodal treatment for head and neck cancer. 2009 , 89, 43-52, viii	18
202	Hyperfractionated or accelerated radiotherapy for head and neck cancer. 2010 ,	25
201	Fractionation Concepts. 2010 , 13-26	
200	A phase I/II study of altered fractionated IMRT alone for intermediate T-stage oropharyngeal carcinoma. 2010 , 186, 489-95	11
199	Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. 2010 , 116, 4533-40	38
198	Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma. 2010 , 32, 939-45	25
197	Radiobiological modelling of the therapeutic ratio for the addition of synchronous chemotherapy to radiotherapy in locally advanced squamous cell carcinoma of the head and neck. 2010 , 22, 125-30	23
196	Hypothyroidism after radiotherapy for nasopharyngeal cancer patients. 2010 , 76, 1133-9	39
195	Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study. 2010 , 77, 9-15	23
194	Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (nonparotid): a better outcome with surgery and adjuvant radiotherapy. 2003 , 113, 1827-33	95
193	Handbook of Evidence-Based Radiation Oncology. 2010 ,	32
192	A prospective, randomized, multi-center trial to investigate Actovegin in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2010 , 97, 113-8	15
191	Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. 2010 , 11, 553-60	90
190	Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. 2010 , CD006387	32

La radiothiapie conformationnelle en modulation dintensit (RCMI) : vers un nouveau standard 189 en radiothfapie des cancers ORL?, 2011, 128, 284-291 Intensity-modulated radiation therapy (IMRT): toward a new standard for radiation therapy of head 188 15 and neck cancer?. 2011, 128, 241-7 Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial. Radiotherapy and Oncology, 2011, 187 16 5.3 100, 56-61 Advancing radiation oncology through scientific publication--100 volumes of Radiotherapy and 186 5.3 Oncology. Radiotherapy and Oncology, 2011, 100, 1-6 Practical TimeDose Evaluations, or How to Stop Worrying and Learn to Love Linear Quadratics. 185 1 **2011**. 3-50 184 How can we overcome tumor hypoxia in radiation therapy?. **2011**, 52, 545-56 129 183 Head and neck cancers. 2011, 9, 596-650 141 182 Radiotherapy: technical aspects. 2011, 39, 698-704 9 Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks): an alternative in 181 12 the treatment of locally advanced head and neck cancer. 2011, 187, 651-5 180 Radiotherapie. 2011, 54, 554-559 Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly 179 30 cisplatin for Stage III and IVa head-and-neck cancer. 2011, 79, 1081-8 Treatment outcomes of locally advanced oropharyngeal cancer: a comparison between combined modality radio-chemotherapy and two variants of single modality altered fractionation 6 178 radiotherapy. 2011, 80, 1030-6 Hypofractionated accelerated radiotherapy with concurrent carboplatin for locally advanced 177 17 squamous cell carcinoma of the head and neck. 2011, 23, 34-9 Correlation of currently used radiobiological parameters with local control and acute and late mucosal toxicity in randomised studies of altered fractionation for locally advanced head and neck 176 17 cancer. 2011, 23, 29-33 Indications for Adjuvant Chemotherapy and Radiation Therapy. 2012, 445-449 175 1 A phase III study of late course accelerated hyperfractionated radiotherapy versus conventionally 16 174 fractionated radiotherapy in patients with nasopharyngeal carcinoma. 2012, 35, 600-5 Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 173 235 randomised trial. 2012, 13, 145-53 Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. 2012, 62, 400-22 172 252

171	EORTC Radiation Oncology Group: 50 years of continuous accomplishments. 2012 , 10, 150-159		1
170	Oropharynx cancer. 2012 , 36, 334-415		5
169	Treatment outcome of patients with stages I-II nasopharyngeal carcinoma after late course accelerated hyperfractionation radiotherapy alone. 2012 , 48, 1058-1063		11
168	Tumour Repopulation During Treatment for Head and Neck Cancer: Clinical Evidence, Mechanisms and Minimizing Strategies. 2012 ,		
167	Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study. 2012 , 188, 666-70		22
166	Improved survival among patients with base of tongue and tonsil cancer in the United States. 2012 , 23, 153-64		11
165	A prospective investigation of swallowing, nutrition, and patient-rated functional impact following altered fractionation radiotherapy with concomitant boost for oropharyngeal cancer. 2012 , 27, 32-45		27
164	High-dose radiotherapy alone for patients with T4-stage laryngeal cancer. 2013 , 189, 632-8		7
163	Acute mucosal reactions in patients with head and neck cancer. Three patterns of mucositis observed during radiotherapy. 2013 , 189, 547-51		13
162	Contemporary radiotherapy in head and neck cancer: balancing chance for cure with risk for complication. 2013 , 22, 579-98		13
161	Strategies for non-resectable head and neck cancer. 2013 , 14, 492-504		11
160	Revising the radiobiological model of synchronous chemotherapy in head-and-neck cancer: a new analysis examining reduced weighting of accelerated repopulation. 2013 , 86, 157-63		16
159	Multidisciplinary care of the patient with head and neck cancer. 2013 , 22, 179-215		15
158	A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach. <i>Radiotherapy and Oncology</i> , 2013 , 106, 333-40	5.3	56
157	Ionizing radiation, ion transports, and radioresistance of cancer cells. 2013 , 4, 212		38
156	E. Rehabilitation of Patients with Head and Neck Cancer: Swallowing. 2013,		
155	Correlation of Computerized Tomography density patterns of lymph nodes with treatment results and outcome in head and neck cancer patients treated by 2 different chemoradiotherapy schedules. 2014 , 10, 284-93		3
154	Tumor Radiation Biology. 2014 , 97-119		О

153	Final results of a phase II single-institutional trial with hyperfractionated radiation therapy (HFX) and four-weekly continuous cisplatin in locally advanced head and neck carcinoma. 2014 , 16, 555-60		2
152	[Long-term results and cause of failure analysis in larynx cancer patients irradiated conventionally and with accelerated fractionation schedules in 1995-1998]. 2014 , 68, 320-7		
151	Altered fractionation schedules in radiation treatment: a review. 2014 , 41, 730-50		24
150	Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512). 2014 , 89, 958-963		61
149	Influence of periodontitis on the experience of oral mucositis in cancer patients undergoing head and neck radiotherapy: a pilot study. 2014 , 22, 2119-25		12
148	The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?. 2014 , 88, 254-62		358
147	Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. 2014 , 89, 13-20		142
146	Cancer of the head and neck. 2014 , 158-183		
145	Concurrent hyperfractionated chemoradiotherapy for head and neck squamous cell carcinoma: the prognostic impact of the overall treatment time and completion rates of chemotherapy. 2015 , 4, 446		1
144	Head and Neck Cancer. 2015 , 61-89		
143	Clinical radiobiology of head and neck cancer: the hypothesis of stem cell activation. 2015 , 17, 469-76		4
143	Clinical radiobiology of head and neck cancer: the hypothesis of stem cell activation. 2015 , 17, 469-76 Incorporating Genetic Biomarkers into Predictive Models of Normal Tissue Toxicity. 2015 , 27, 579-87		28
142	Incorporating Genetic Biomarkers into Predictive Models of Normal Tissue Toxicity. 2015 , 27, 579-87 Final Report of Radiation Therapy Oncology Group Protocol 9003: Provocative, but Limited	5-3	28
142	Incorporating Genetic Biomarkers into Predictive Models of Normal Tissue Toxicity. 2015 , 27, 579-87 Final Report of Radiation Therapy Oncology Group Protocol 9003: Provocative, but Limited Conclusions From Exploratory Analyses. 2015 , 92, 715-7 The origins of translational radiation oncology - In memoriam H. Rodney Withers (21 September	5-3	28
142 141 140	Incorporating Genetic Biomarkers into Predictive Models of Normal Tissue Toxicity. 2015, 27, 579-87 Final Report of Radiation Therapy Oncology Group Protocol 9003: Provocative, but Limited Conclusions From Exploratory Analyses. 2015, 92, 715-7 The origins of translational radiation oncology - In memoriam H. Rodney Withers (21 September 1932-25 February 2015). <i>Radiotherapy and Oncology</i> , 2015, 115, 1-2 Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment.	5.3	28
142 141 140	Incorporating Genetic Biomarkers into Predictive Models of Normal Tissue Toxicity. 2015, 27, 579-87 Final Report of Radiation Therapy Oncology Group Protocol 9003: Provocative, but Limited Conclusions From Exploratory Analyses. 2015, 92, 715-7 The origins of translational radiation oncology - In memoriam H. Rodney Withers (21 September 1932-25 February 2015). Radiotherapy and Oncology, 2015, 115, 1-2 Exploiting biological and physical determinants of radiotherapy toxicity to individualize treatment. 2015, 88, 20150172 Waluation de läfficacit din laser de basse hergie dans le traitement des mucites radio-induites, versus traitement conventionnel, chez des patients traits pour un carcinome indiffènci du	5.3	28 2 1 30

135 Hyperfractionated radiotherapy. **2015**, 27, 65

134	Jack Fowler's 90th birthday and contributions to fractionation. 2015 , 27, 1-2	
133	Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis. 2015 , 37, 670-6	10
132	Foam dressing with epidermal growth factor for severe radiation dermatitis in head and neck cancer patients. 2016 , 13, 390-3	4
131	Impaired vocal cord mobility in T2N0 glottic carcinoma: Suboptimal local control with Radiation alone. 2016 , 38, 1832-1836	18
130	AHNS Series: Do you know your guidelines?Principles of radiation therapy for head and neck cancer: A review of the National Comprehensive Cancer Network guidelines. 2016 , 38, 987-92	19
129	Severe late dysphagia and cause of death after concurrent chemoradiation for larynx cancer in patients eligible for RTOG 91-11. 2016 , 57, 21-6	23
128	Fractionation Concepts. 2016 , 17-34	1
127	Management of the Neck. 2016 , 738-762.e4	
126	Overview. 2016 , 561-569.e3	
125	The Impact of Radiation Treatment Time on Survival in Patients With Head and Neck Cancer. 2016 , 96, 967-975	49
124	Tratamiento no quirígico en cilcer epidermoide de orofaringe avanzado. Anlisis de resultados oncolgicos en funcil del subsitio tumoral y fraccionamiento de radioterapia. 2016 , 68, 355-362	
123	Optimal fractionation in radiotherapy with multiple normal tissues. 2016 , 33, 211-52	20
122	Head and Neck Cancer. 2017 , 91-126	2
121	Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer. 2017 , 123, 1555-1565	9
120	Comprehensive Overview: Definitive Radiotherapy and Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer. 2017 , 151-176	3
119	Critical Issues in Head and Neck Oncology. 2017 ,	
118	Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. 2017 , 18, 1221-1237	156

117	Patterns of fractionation for patients with T2N0M0 glottic larynx cancer undergoing definitive radiotherapy in the United States. 2017 , 72, 110-116	7
116	[Reasons for the terms "radiosurgery" and "Gamma Knife"]. 2017 , 65, 775-776	
115	Spatiotemporally Optimal Fractionation in Radiotherapy. 2017 , 29, 422-437	9
114	Accelerated or hyperfractionated radiotherapy for esophageal carcinoma: a meta-analysis of randomized controlled trials. 2017 , 10, 2971-2981	1
113	Dose dependence of accelerated repopulation in head and neck cancer: Supporting evidence and clinical implications. <i>Radiotherapy and Oncology</i> , 2018 , 127, 20-26	8
112	Altered fractionation radiotherapy with or without chemotherapy in the treatment of head and neck cancer: a network meta-analysis. 2018 , 11, 5465-5483	3
111	Machine Learning and Radiogenomics: Lessons Learned and Future Directions. 2018 , 8, 228	41
110	Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the Hypopharynx: Long-term Outcomes and Toxicity. 2018 , 38, 3543-3549	8
109	Patterns of utilization and comparative efficacy of altered fractionation and concurrent chemoradiation for treatment for T2N0M0 glottic carcinoma. 2019 , 8, 267-278	
108	The Linear-Quadratic Model and Implications for Fractionation. 2019 , 31, 673-677	8
107	Rationale for hypofractionation. 2019 , 23, 500-502	3
106	The 100 most cited manuscripts in head and neck cancer: a bibliometric analysis. 2019 , 133, 936-942	6
105	DAHANCA 9 - a randomized multicenter study to compare accelerated normo-fractionated radiotherapy with accelerated hyperfractionated radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC). 2019 , 58, 1502-1505	5
104	A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma. 2019 , 58, 1495-1501	14
103	[Individualization of dose and fractionation of radiotherapy for head and neck cancers]. 2019, 23, 784-788	
102	Optimized Hypofractionation Can Markedly Improve Tumor Control and Decrease Late Effects for Head and Neck Cancer. 2019 , 104, 272-278	14
101	Neck management in head and neck squamous cell carcinomas: where do we stand?. 2019, 36, 40	3
100	Optimal modality selection in external beam radiotherapy. 2019 , 36, 361-380	3

99	Cancer of the Head and Neck. 2020 , 999-1033.e7		O
98	The role of concomitant chemoradiotherapy in AJCC 7 edition T1-2N1 oropharyngeal carcinoma in the human papillomavirus era. 2020 , 110, 104882		O
97	Impact of honey on radiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. 2020 , 9, 1431-1441		3
96	Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2020 , 150, 18-25	5.3	10
95	Four decades with ESTRO. Radiotherapy and Oncology, 2020 , 142, 1-5	5.3	2
94	Altered fractionation diminishes importance of tumor volume in oropharyngeal cancer: Subgroup analysis of ARTSCAN-trial. 2020 , 42, 2099-2105		1
93	Most Cited Articles in Head and Neck Oncology. 2021 , 100, 1061S-1072S		
92	Three discipline collaborative radiation therapy (3DCRT) special debate: We should treat all cancer patients with hypofractionation. 2020 , 21, 7-14		2
91	Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer. 2020 , 21, 69-76		1
90	DAHANCA 28: A phase I/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV/p16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity.	5.3	9
89	Low-risk human papilloma virus positive oropharyngeal cancer with one positive lymph node: Equivalent outcomes in patients treated with surgery and radiation therapy versus surgery alone. 2021 , 43, 1759-1768		0
88	Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina. 2021 , 38, 2613-2630		1
87	Retreatment in locally recurrent nasopharyngeal carcinoma: Current status and perspectives. 2021 , 41, 361-370		6
86	[Low-dose irradiation of non-malignant diseases: Did we throw the baby out with the bathwater?]. 2021 , 25, 279-282		1
85	Up-front neck dissection followed by chemoradiotherapy for T1-T3 hypopharyngeal cancer with advanced nodal involvement. 2021 , 43, 3810-3819		1
84	Clinical Principles and Applications of Chemoirradiation. 2006 , 39-55		3
83	Multidisciplinary Management of Oral Cavity and Maxillary Sinus Cancers. 2011 , 363-380		1
82	Multidisciplinary Management of Hypopharyngeal Carcinoma. 2011 , 431-455		2

(2000-1998)

81	Altered fractionation: radiobiological principles, clinical results, and potential for dose escalation. 1998 , 93, 101-28	9
80	Strategies for Protecting Normal Tissue in the Treatment of Head and Neck Cancer. 2005 , 227-237	2
79	Altered Fractionation. 2005, 125-144	2
78	Oral Mucositis. 2017 , 53-78	1
77	Tumor Biology⊞ Impact on Clinical Cure Rates. 2009 , 323-334	4
76	Post-Radiation Dysphagia. 2008, 67-79	2
75	Head and Neck Tumors. 2003 , 357-373	2
74	Thermoradiotherapy for Head and Neck Tumors. 1996 , 49-67	2
73	Bestrahlungsplanung. 1996, 219-268	1
72	Hyperfractionation. 1993 , 45-50 Head and Neck Tumors. 1999 , 559-581	0
7 ¹	Radiation Therapy and Management of the Cervical Lymph Nodes and Malignant Skull Base Tumors. 2010 , 1682-1701	1
69	Early Treatment with Radiation and Chemotherapy. 2010 , 129-165	1
68	Fractionation Effects in Clinical Practice. 2010 , 40-54	1
67	A PHASE I/II TRIAL OF TRANSURETHRAL SURGERY COMBINED WITH CONCURRENT CISPLATIN, 5-FLUOROURACIL AND TWICE DAILY RADIATION FOLLOWED BY SELECTIVE BLADDER PRESERVATION IN OPERABLE PATIENTS WITH MUSCLE INVADING BLADDER CANCER. 1998 , 1673-1677	2
66	The current status of bladder preservation in the treatment of muscle invasive bladder cancer. 2000 , 164, 627-32	6
65	Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules. 2010 , 33, 137-43	13
64	Improving cancer outcomes through radiotherapy. Lack of UK radiotherapy resources prejudices cancer outcomes. 2000 , 320, 198-9	19

63	Adjuvant Chemotherapy in Advanced Head and Neck Cancer. 1997 , 2, 135-141	3
62	Head and Neck Cancer: Altered Fractionation Schedules. 1999 , 4, 11-16	9
61	Definitive Intensity-modulated Radiation Therapy in Elderly Patients with Locally Advanced Oropharyngeal Cancer. 2017 , 31, 455-459	6
60	Response-Guided Dosing in Cancer Radiotherapy. 2021 , 1-37	
59	Uninterrupted moderately accelerated radiotherapy in the treatment of unresectable/advanced head and neck cancer: one institution's experience and a comparative review. 2000 , 23, 149-54	2
58	Head and Neck Cancer. 2001 , 163-176	
57	Clinical Trials in Advanced Unresectable Head and Neck Cancer. 2003, 461-474	
56	Organ Preservation in Head and Neck Cancer. 2003 , 475-490	
55	Dermatologische R\u00dftgenweichstrahltherapie. 2004 , 223-229	
54	Tumoren im Kopf- und Halsbereich. 2004 , 1417-1452	1
53	Ciruga y oncologa de cabeza y cuello - Pages 695-712. 2004 , 695-712	
52	Strahlentherapie. 2004 , 425-463	
51	Lippen-, MundhBlen- und Oropharynxtumoren. 2006 , 3342-3381	1
50	Alteredfractionation radiotherapy in head and neck cancer. 2007, 33, 283-288	
49	Altered fractionated radiotherapy has a survival benefit for head and neck cancers: Is it true?. 2007 , 33, 289-292	1
48	Basics of Radiation Therapy. 2008 , 417-448	1
47	Cancer of the Head and Neck. 2008 , 1177-1228	1
46	Radiotherapy for stage IV oropharyngeal cancer. 2008 , 34, 530-535	

[1997-2009]

45	Oropharynx: Epidemiology and Treatment Outcome. 2009 , 15-29
44	Cancer of the Oropharynx. 2010 , 546-587
43	Radiotherapy for Head and Neck Cancer. 2010 , 1030-1050
42	Oropharyngeal Cancer. 2010 , 117-129
41	Tumori maligni epiteliali dell ō rofaringe. 2011 , 309-319
40	Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers. 2011 , 471-481
39	Multidisciplinary Management of Oropharynx Carcinomas. 2011 , 401-430
38	Introduction. 2011 , 1-10
37	Management of the Neck. 2012 , 731-755
36	Overview. 2012 , 543-551
35	Management of human papillomavirus-induced oropharynx cancer. 2012 , 368-71
34	Kopf-Hals-Tumoren. 2013 , 431-515
33	Radiotherapie. 2014 , 75-86
32	Upper Respiratory and Digestive System: Pharynx, Larynx, and Xerostomia. 2014 , 167-188
31	Cancer of the Head and Neck. 2014 , 1037-1070.e6
30	Oncology. 1994 , 161, 149-51
29	Rachen. 1996 , 347-368
28	Lippen-, Mundhtilen- und Oropharynx-Tumoren. 1997 , 421-449

27	Altered Fractionation Strategies in Radiation Oncology for the Head and Neck Cancer Patient. 1997 , 9, 425-432	
26	Kopf- und Halstumoren. 1998 , 436-475	1
25	Oral Cavity, Pharynx, and Larynx Cancer.	
24	Head and Neck Tumors: Viewpoint E ractionated Radiation Therapy and Chemotherapy. 2015 , 549-562	
23	Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers. 2016 , 555-567	
22	Multidisciplinary Management of Oral Cavity and Maxillary Sinus Cancers. 2016 , 405-428	
21	Multidisciplinary Management of Hypopharyngeal Carcinoma. 2016 , 511-537	
20	Multidisciplinary Management of Oropharynx Carcinomas. 2016 , 475-510	
19	ROLE OF FLUCONAZOLE IN THE PREVENTION OF RADIATION-INDUCED MUCOSITIS IN HEAD AND NECK CANCER PATIENTS. 2016 , 3, 2886-2889	
18	Accelerated Fractionation Radiotherapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma. 2017 , 8,	
17	Radiotherapy and Radiosensitizers. 2018 , 51-57	
16	ALTERED FRACTIONATION RADIOTHERAPY FOR HEAD AND NECK CANCER. 2019 , 17, 368-376	
15	Intensity-Modulated Radiation Therapy in the Management of Head and Neck Cancer. 2005, 115-124	O
14	Kopf-Hals-Tumoren. 2006 , 373-450	
13	Cancer of the Oral Cavity and Oropharynx. 2008 , 37-59	
12	Altered fractionation in radiation therapy for head and neck cancer. 1994 , 160, 456	
11	Altered and conventional fractionated radiotherapy in locoregional control and survival of patients with squamous cell carcinoma of the larynx, oropharynx, and hypopharynx. 2006 , 47, 42-52	6
10	Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. 2022 , 32, 35-40	1

9 The biological basis of fractionation in radiotherapy. **2002**, **4**, 161-166

8	Radiation Oncology. 2022 , 241-249	
7	The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma. 2022 , 130, 105907	
6	Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy. 2022 , 17,	O
5	Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients with Head and Neck Region Tumours. 2022 , 10, 1484	
4	Hypoxia in relationship to tumor volume using hypoxia PET-imaging in head & neck cancer [A scoping review. 2022 , 36, 40-46	Ο
3	Head and Neck Cancer Predictive Risk Estimator to Determine Control and Therapeutic Outcomes of Radiotherapy (HNC-PREDICTOR): Development, international multi-institutional validation, and web-implementation of clinic-ready model-based risk stratification for head and neck cancer. 2022 ,	0
2	Effect of Ablative Dose Irradiation on Redistribution and Radioresponse in a Mouse Xenograft Model. 2022 ,	O
1	A COMPARATIVE PROSPECTIVE STUDY BETWEEN STANDARD AND ALTEREDFRACTIONATED RADIOTHERAPY FOR LOCALLY ADVANCED HEAD AND NECKSQUAMOUS CELL CARCINOMA. 2023 , 11-14	О